Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Chronic Pancreatitis
Interventions: Creon36™; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 30 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Low Grade Upper Tract Urothelial Carcinoma
Interventions: Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 25
States / cities: Loma Linda, California • Los Angeles, California • Tampa, Florida + 22 more

Conditions: SARS-CoV-2
Interventions: Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose; Drug · Biological
Lead sponsor: Sean Liu; Other
Eligibility: 18 Years to 59 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab, LymphDetect assay, Surgery +/- neoadjuvant pembrolizumab; Drug · Radiation · Diagnostic Test + 1 more
Lead sponsor: Kevin Contrera; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Keratoconjunctivitis Sicca
Interventions: Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution; Drug
Lead sponsor: Mitotech, SA; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Chronic Kidney Diseases, Obesity
Interventions: SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide; Behavioral · Drug
Lead sponsor: Srinvasan Beddhu; Other
Eligibility: 20 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Stanford, California • Salt Lake City, Utah

Conditions: Idiopathic Short Stature
Interventions: Vosoritide Injection, Human Growth Hormone, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2036
U.S. locations: 35
States / cities: California City, California • Los Angeles, California • Oakland, California + 28 more

Conditions: Acute-graft-versus-host Disease
Interventions: AAT, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more

Conditions: Advanced Solid Tumors
Interventions: Golvatinib, Lenvatinib; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Kidney Transplantation
Interventions: bleselumab, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 21
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 16 more

Conditions: Hip Pain Chronic
Interventions: Transmuscular Quadratus Lumborum Block, Pericapsular injection, Bupivacaine Hydrochloride; Procedure · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: [18F]- PARPi, PET/CT Scans; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Interventions: ASTX727; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more

Conditions: Hyperthermia
Interventions: This protocol will utilize a sauna as the primary method of detoxification.; Other
Lead sponsor: Bastyr University; Other
Eligibility: 21 Years to 35 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Low Back Pain
Interventions: Ibuprofen, Osteopathic manipulative treatment; Drug · Procedure
Lead sponsor: Albert Einstein Healthcare Network; Other
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neurotrophic Keratopathy
Interventions: MR-146; Genetic
Lead sponsor: Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Sun City, Arizona • Tucson, Arizona • Glendale, California + 8 more

Conditions: Polycystic Ovary Syndrome
Interventions: Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Congenital Adrenal Hyperplasia (CAH)
Interventions: Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: ETBX-021; Biological
Lead sponsor: NantBioScience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: El Segundo, California • Sioux Falls, South Dakota

Conditions: Idiopathic Parkinson's Disease
Interventions: CVT-301; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 30 Years to 86 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 55
States / cities: Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more

Conditions: Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions: Iomab-B, Conventional Care, HCT; Drug · Procedure
Lead sponsor: Actinium Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 22
States / cities: Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more

Conditions: Mature Cataracts
Interventions: DYME; Drug
Lead sponsor: Aqumen Biopharmaceuticals, N.A.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 9
States / cities: Inglewood, California • Miami, Florida • Des Peres, Missouri + 6 more

Conditions: HIV, Inflammation, Atherosclerosis
Interventions: Folic Acid, Placebo, Low Dose Methotrexate; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Fat Malabsorption in Chronic Pancreatitis

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer

A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Sit Less, Interact and Move More (SLIMM) 2 Study

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

Transmuscular Quadratus Lumborum Block Plus Pericapsular Injection vs Pericapsular Injection

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Sauna Detoxification Study: Pilot Feasibility

Acute Low Back Pain in the Emergency Department Treated With Osteopathic Manipulative Treatment Versus NSAIDs

A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in Participants With Stage 1 or 2 Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery

PET/CT Imaging Companion Study To ACTG A5314